Possible ligand-receptor interactions for NK1 antagonists as observed in their crystal structures

被引:28
作者
Boks, GJ [1 ]
Tollenaere, JP [1 ]
Kroon, J [1 ]
机构
[1] UNIV UTRECHT, BIJVOET CTR BIOMOL RES, DEPT CRYSTAL & STRUCT CHEM, NL-3584 CH UTRECHT, NETHERLANDS
关键词
NK1; antagonists; crystal structures; intermolecular interactions; ligand-receptor interactions;
D O I
10.1016/S0968-0896(96)00267-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Crystal structures of nine non-peptide tachykinin NK1 antagonists have been analysed for the intermolecular interactions of their pharmacophoric groups with neighbouring molecules in the crystals. Experimental data on interaction geometries of these antagonists with their environment can be of help in understanding the mechanism of binding to the human NK1 receptor. Several interaction geometries have been identified that are consistent with both structure-activity relationships and reported receptor interactions for the compounds analysed. In addition, an interaction site for the side-chain of Gln-165 in the human NK1 receptor that is probably involved in donating a hydrogen bond to the benzylamino nitrogen or benzylether oxygen of the quinuclidine and piperidine antagonists is explicitly postulated. Also, a superposition based on pharmacophoric elements in the crystal structure conformations of two prototypic NK1 antagonists, CP-96,345 (I) and CP-99,994 (4), suggests how both compounds might interact with the human NK1 receptor in a similar manner. (C) 1997 Elsevier Science Ltd.
引用
收藏
页码:535 / 547
页数:13
相关论文
共 33 条
[21]   THE DISCOVERY OF (2S,3S)-CIS-2-(DIPHENYLMETHYL)-N-[(2-METHOXYPHENYL)METHYL]-1-AZABICYCLO[2.2.2]OCTAN-3-AMINE AS A NOVEL, NONPEPTIDE SUBSTANCE-P ANTAGONIST [J].
LOWE, JA ;
DROZDA, SE ;
SNIDER, RM ;
LONGO, KP ;
ZORN, SH ;
MORRONE, J ;
JACKSON, ER ;
MCLEAN, S ;
BRYCE, DK ;
BORDNER, J ;
NAGAHISA, A ;
KANAI, Y ;
SUGA, O ;
TSUCHIYA, M .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (14) :2591-2600
[22]   N-ACYL-L-TRYPTOPHAN BENZYL-ESTERS - POTENT SUBSTANCE-P RECEPTOR ANTAGONISTS [J].
MACLEOD, AM ;
MERCHANT, KJ ;
CASCIERI, MA ;
SADOWSKI, S ;
BER, E ;
SWAIN, CJ ;
BAKER, R .
JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (14) :2044-2045
[23]   IDENTIFICATION OF L-TRYPTOPHAN DERIVATIVES WITH POTENT AND SELECTIVE ANTAGONIST ACTIVITY AT THE NK1 RECEPTOR [J].
MACLEOD, M ;
MERCHANT, KJ ;
BROOKFIELD, F ;
KELLEHER, F ;
STEVENSON, G ;
OWENS, AP ;
SWAIN, CJ ;
BAKER, R ;
CASCIERI, MA ;
SADOWSKI, S ;
BER, E ;
STRADER, CD ;
MACINTYRE, DE ;
METZGER, JM ;
BALL, RG .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (09) :1269-1274
[24]   NOVEL, POTENT, AND ORALLY-ACTIVE SUBSTANCE-P ANTAGONISTS - SYNTHESIS AND ANTAGONIST ACTIVITY OF N-BENZYLCARBOXAMIDE DERIVATIVES OF PYRIDO[3,4-B]PYRIDINE [J].
NATSUGARI, H ;
IKEURA, Y ;
KIYOTA, Y ;
ISHICHI, Y ;
ISHIMARU, T ;
SAGA, O ;
SHIRAFUJI, H ;
TANAKA, T ;
KAMO, I ;
DOI, T ;
OTSUKA, M .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (16) :3106-3120
[25]   SMALL-MOLECULE CRYSTAL-STRUCTURES AS A STRUCTURAL BASIS FOR DRUG DESIGN [J].
PASCARD, C .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1995, 51 :407-417
[26]  
REGOLI D, 1994, PHARMACOL REV, V46, P551
[27]   A POTENT NONPEPTIDE ANTAGONIST OF THE SUBSTANCE-P (NK1) RECEPTOR [J].
SNIDER, RM ;
CONSTANTINE, JW ;
LOWE, JA ;
LONGO, KP ;
LEBEL, WS ;
WOODY, HA ;
DROZDA, SE ;
DESAI, MC ;
VINICK, FJ ;
SPENCER, RW ;
HESS, HJ .
SCIENCE, 1991, 251 (4992) :435-437
[28]  
Spek A.L., 1990, ACTA CRYSTALLOGR A, VA46, pC34, DOI DOI 10.1107/S0108767390099780
[29]   SPECIAL ISSUE - MOPAC - A SEMIEMPIRICAL MOLECULAR-ORBITAL PROGRAM [J].
STEWART, JJP .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 1990, 4 (01) :1-45
[30]   IDENTIFICATION OF A SERIES OF 3-(BENZYLOXY)-1-AZABICYCLO[2.2.2]OCTANE HUMAN NK1 ANTAGONISTS [J].
SWAIN, CJ ;
SEWARD, EM ;
CASCIERI, MA ;
FONG, TM ;
HERBERT, R ;
MACINTYRE, DE ;
MERCHANT, KJ ;
OWEN, SN ;
OWENS, AP ;
SABIN, V ;
TEALL, M ;
VANNIEL, MB ;
WILLIAMS, BJ ;
SADOWSKI, S ;
STRADER, C ;
BALL, RG ;
BAKER, R .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (24) :4793-4805